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INTRODUCTION
Multiple myeloma (MM) is a disease of cancerous plasma 
cells that expand in bone marrow, causing symptoms of ane-
mia, hypercalcemia, and osteolytic bone lesions.1 The disease 
is characterized by uncontrolled proliferation of a plasma cell 
clone with an accumulation of monoclonal immunoglobu-
lins.2 Myeloma and stromal cells produce osteoclast activating 
factors, such as IL-6, IL-3, receptor activator nuclear factor 
kappa B ligand (RANKL), TNF-α, and MIP1α, which are re-
sponsible for bone resorption.3-7 Furthermore, myeloma cells 
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induce changes in the bone marrow microenvironment, 
thereby the production of osteoblastic inhibitor factors, such 
as TGF-β, TNF-α, and IL-3, is increased.8,9 Accordingly, an im-
balance in osteoclast and osteoblast activity with the preva-
lence of bone resorption leads to marrow destruction.
The Wnt signaling pathway plays important role in the pro-
cess of osteogenic differentiation and in the maintenance of 
mesenchymal stem cells, as well as in embryonic develop-
ment.10 Several attempts have been made to target the Wnt 
signaling pathway by inhibiting endogenous antagonists and 
by regulating intracellular mediators for the treatment of os-
teogenic disorders.11 Antibodies against endogenous Wnt an-
tagonists, such as sclerostin, have shown bone-forming and 
fracture healing effects.12 Dickkopf 1 (DKK1) is another im-
portant endogenous inhibitor of the canonical Wnt signaling 
pathway, which binds to low density lipoprotein receptor-re-
lated protein (LRP) 5/6, together with Kremen receptor, to in-
hibit the canonical Wnt signaling pathway.13
DKK1 has been extensively investigated in murine models 
of MM where osteolytic lesions occur. Many studies have con-
firmed that the interaction of MM cells with the bone marrow 
microenvironment causes the bone lesions of myeloma.14 
MM cancer cells secrete DKK1, which disrupts the balance of 
osteoblastogenesis and osteoclastogenesis.15 DKK1 disrupts 
the differentiation of mesenchymal stem cells to osteoblast 
lineage cells, and this results in a shift of the RANKL/osteo-
protegerin (OPG) ratio, leading to excessive bone resorption 
and marrow destruction.15 Enhanced bone resorption is not 
followed by neo-matrix deposition due to the inhibition of 
further differentiation of osteoblast precursors by DKK1.16 
Therefore, DKK1 has been a potential therapeutic target for 
the treatment of MM.
Presently approved medications that target bone diseases 
are limited to anti-resorptive agents and bone-anabolic 
agents,17 and bone-protecting anti-resorptive agents have 
failed to confer significant antitumor activities in clinical stud-
ies.18 A small number of papers have reported that the treat-
ment of antibodies against DKK1 not only reduces bone le-
sions but also reduces the tumor burden of the disease.19,20 
However, exact mechanisms remain under investigation. We 
hypothesized that DKK1-inhibiting oligopeptide would bind 
in the place of DKK1 of the Wnt signaling pathway, reducing 
the binding of the overexpressed DKK1 protein by MM cells. 
The present study aimed to develop a cyclized oligopeptide 
containing the NXI motif already known in DKK1 and to test 
the effects of the oligopeptide on tumor burden.
MATERIALS AND METHODS
Synthesis and purification of peptides
The peptide consisted of 10 amino acids with one disulfide 
bond; it contains NXI motif, which is found in DKK1. Peptides 
were synthesized via Fmoc solid phase peptide synthesis us-
ing ASP48S (Peptron Inc., Daejeon, Korea) and purified via 
the reverse phase high-performance liquid chromatography 
using a Vydac Everest C18 column (250×22 mm, 10 μm). Elu-
tion was carried out with a water-acetonitrile linear gradient 
[3–40% (v/v) of acetonitrile] containing 0.1% (v/v) trifluoro-
acetic acid. Molecular weights of the purified peptide were 
confirmed using Liquid Chromatography/Mass Spectrometry 
(Agilent HP1100 series, Agilent Technologies, Waldbronn, 
Germany).
Cell culture
MOPC315.BM.Luc cells21 were obtained from Bogen Lab. 
Briefly, cells were developed from a MOPC315 cell line 
through s.c. injection twice to obtain MOPC315.4 and i.v. in-
jection to obtain final cell line MOPC315.BM. Then, cells were 
tagged with luciferase gene. Cells were cultured in RPMI 1640 
medium supplemented with fetal bovine serum (FBS) and 
penicillin-streptomycin (Welgene, Gyeongsan, Korea). ST2 
cells were cultured in dulbecco’s modified eagle’s medicum 
medium, and luciferase transfected MC3T3-E1 cells were cul-
tured in alpha-minimum essential medium with FBS and 
penicillin-streptomycin.
Nuclear magnetic resonance (NMR) spectroscopy
Nuclear magnetic resonance (NMR) spectra were acquired at 
283 K on a Bruker DRX-500 spectrometer equipped with a tri-
ple resonance probe with an x, y, and z-shielded pulsed-field 
gradient coil. Two-dimensional (2D) NMR spectra were re-
corded in a phase-sensitive mode using time proportional 
phase increment for quadrature detection in the t1 domain. 
Total correlation spectroscopy (TOCSY)22 using a dipsi-2 spin-
lock pulse sequence with a mixing time of 70 ms and nuclear 
overhauser enhancement spectroscopy (NOESY)23 with mix-
ing times of 250–600 ms were performed. All NMR spectra were 
acquired with 2048 complex data points in t2 and 256 incre-
ments in the t1 dimension, with 64 scans per each increment. 
All NMR data were processed using nmrPipe/nmrDraw or 
XWIN-NMR software (Bruker Instruments, Karlsruhe, Ger-
many) and analyzed using the Sparky 3.95 program.
Structure calculations 
Distance restraints were derived from the NOESY spectra in 
100% deuterated DMSO solution. The solution structures 
were calculated using the hybrid distance geometry and dy-
namical simulated annealing (SA) protocol using the CNS 1.1 
program on a Linux workstation. Final structures were ana-
lyzed using the PROCHECK20 and MOLMOL programs.24
Surface plasmon resonance (SPR) assay
An surface plasmon resonance (SPR) 36 assay was performed 
by the Gyeonggi Bio Center (Suwon, Korea), using a ProteOn 
XPR36 instrument (Bio-Rad Laboratories, Hercules, CA, USA). 
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LRP5 E1 domains were tethered (immobilized) onto a biosen-
sor chip surface. Then, five different concentrations (1, 3, 10, 
30, and 100 µM) of the oligopeptide were passed over the 
LRP5 E1 domain in order for binding interactions to occur. 
The Langmuir model of the ProteOn ManagerTM program (Bio-
Rad Laboratory) was used for SPR data analysis. 
Transfected MC3T3-E1 cell luciferase reporter assay
In the Wnt signaling study, MC3T3-E1 cells were transfected 
as previously reported.25 Seeded cells were treated in different 
concentrations (50 nM, 500 nM, 5 µM) of oligopeptide along 
with Wnt7a and DKK1 for 24 hours. Cells were collected after 
lysis in 1X passive lysis buffer (Promega, Madison, WI, USA) 
and measured for luciferase reporter activity following the 
Promega protocol.
ST2 cell alkaline phosphatase staining assay  
(ALP staining)
ST2 cells were seeded and treated with Wnt7a, DKK1, and dif-
ferent concentrations of oligopeptide: 50 nM, 500 nM, 5 µM, 
and 50 µM. After 48 hours, alkaline phosphatase (ALP) stain-
ing assay was performed using an ALP kit (Sigma-Aldrich, St. 
Louis, MO, USA) according to the manufacturer’s protocol. 
Images were taken using an Olympus IX73 inverted micro-
scope at magnification ×40.
Mice and injections
Five-week-old BALB/c female mice were purchased (Orient-
bio, Seongnam, Korea) and housed with five mice per cage at 
the Yonsei Biomedical Research Institute. Mice were main-
tained for 1 week to allow them to adapt to the new environ-
ment. A total of 30 mice were divided into three groups (ten 
mice each): a negative control, a positive control, and an ex-
perimental group. The negative control group received 150 µL 
of PBS via tail vein injection, while the other 20 mice received 
2×105 MOPC315.BM.Luc cells in 150 µL of PBS via tail vein in-
jection. Five days after the cell injection, oligopeptide (75 
µg/150 µL/mouse) and vehicle (150 µL of phosphate-buffered 
saline/mouse) treatments were administered via subcutane-
ous injection 6 days per week for 4 weeks.
Bioluminescence imaging (BLI)
All mice underwent bioluminescence imaging (BLI) using an 
IVIS Spectrum (Caliper-Xenogen, Hopkinton, MA, USA) 5 days 
after the tail vein cell injection and 4 weeks after oligopeptide 
treatment. D-luciferin (VivoGlo Luciferin, Promega, Madison, 
WI, USA) was injected (150 mg/kg) with an anesthesia mix-
ture of tiletamine+zolazepam (30 mg/kg) and xylazine (10 
mg/kg) 10 minutes prior to taking the image via intraperito-
neal injection. Bioluminescence was measured from the dor-
sal and ventral sides of mice. Images were evaluated with Liv-
ing Image® 4.4 (Caliper-Xenogen, Hopkinton, MA, USA).
Ethics statement
All experiments were conducted according to the guidelines for 
the care and use of laboratory animals (National Research Coun-
cil, Washington, DC, USA), the IACUC, and the 3R principles. 
Statistics
Values are expressed as mean±standard deviation and medi-
an, and statistical analysis was performed using and Graph-
Pad Prism 5 software. Mann-Whitney U test was used to ana-
lyze statistical significance, and differences were considered 
to be statistically significant when p<0.05.
RESULTS
Solution structures of the cyclized oligopeptide
Once the individual spin systems had been classified, back-
bone sequential resonance assignment was easily completed 
via dαN (i, i+1) NOE connectivities in the 2D-NOESY spectra. 
The side chain assignment was performed via TOCSY con-
nectivities (Fig. 1A). All NOEs were observed at mixing times 
of 600 ms. A total of 100 starting structures were calculated in 
the initial SA stage. The 20 lowest-energy structures (<SA>k) 
were selected out of the 100 final simulated-annealing struc-
Fig. 1. NMR structure of cyclized oligopeptide. (A) 2D TOCSY spectrum of 
DKK1 (1 mM) in 100% DMSO at pH 7.0, 283 K, recorded with a spin-lock 
mixing time of 70 ms. The spectrum shows the identification of amino acid 
spin systems based on scalar correlation of the backbone amide protons of 
(ω2), with the respective side-chain protons (ω1) of each spin system. (B) A 
backbone superposition of the energy-minimized average structure (<SA>kr) 
over the family of 20 final SA structures (<SA>kr). (C) A ribbon diagram of 
DKK1 with side-chain orientations is displayed as a stick model. NMR, 
nuclear magnetic resonance; 2D, two-dimensional; TOCSY, total correla-
tion spectroscopy; DKK1, dickkopf 1; SA, simulated annealing.
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tures for structural analysis. The average structure was gener-
ated from the geometrical average of 20 structure coordinates 
and was subjected to restrained energy minimization to cor-
rect bond length and angle distortions. The average NMR struc-
ture exhibited 0.68-Å root-mean-square deviation for backbone 
atoms with respect to 20 (<SA>k) structures. A best-fit super-
position of all final structures and the backbone conformation 
for the average restrained-energy minimized structure (<SA>kr) 
are displayed in Fig. 1B. The overall fold of the cyclized oligo-
peptide is presented as a ribbon diagram in Fig. 1C. The cyclized 
oligopeptide shows a loop conformation with no regular sec-
ondary structure.
Cyclized oligopeptide binds to the LRP5 E1 site and 
targets Wnt signaling
The binding activity increased as the flowing oligopeptide 
concentration increased from 1 µM to 100 µM (Fig. 2A). 
MC3T3-E1-S-Top cells were treated with Wnts, Wnt inhibitors, 
and oligopeptide. When the cells were treated with Wnt3a 
and DKK1, the activity increased as the concentration of oli-
gopeptide increased; however, when treated with sclerostin, 
the activity could not overcome the inhibition effect (Fig. 2B). 
Similar results were observed with Wnt7a treatment (Fig. 2C). 
These results suggest that the oligopeptide is relatively DKK1 
specific and that the oligopeptide targets the Wnt signaling 
pathway, abrogating the inhibition effects of DKK1.
Cyclized oligopeptide reverses the inhibitory effect of 
DKK1 on osteoblasts in vitro
ST2 cells were treated with Wnt7a, DKK1, and oligopeptide. 
Wnt7a treatment increased ALP and OPG mRNA expression 
levels, and the addition of DKK1 decreased mRNA expression 
levels. However, when cells were treated with oligopeptide, 
the mRNA expressions of ALP and OPG increased again (Fig. 
3A). This result indicated that the oligopeptide activates the 
canonical Wnt signaling that is inhibited by DKK1. To further 
confirm this result, ST2 cells were treated with Wnt7a, DKK1, 
and oligopeptide for ALP staining assay. The results of the ALP 
staining assay were similar to those seen in the RT-PCR. Cells 
treated with only Wnt7a expressed a stronger color, and the 
treatment of DKK1 decreased the staining. Cells treated with 
Wnt7a, DKK1, and oligopeptide could overcome the inhibi-
tion effect of DKK1 dose dependently, shown by the increase 
in staining intensity (Fig. 3B). These results together suggested 
that this oligopeptide has bone-anabolic effects in vitro.
Cyclized oligopeptide inhibits tumor growth in a 
multiple myeloma mouse model
To determine the effect of oligopeptide on MM cell growth in 
vivo, DKK1 expression was confirmed. The mRNA expression 
of both DKK1 and β-catenin were detected (Fig. 3C), indicat-
ing that the canonical Wnt signaling pathway may have cer-
tain effects on MM progression and bone lesions. After the ex-
pression of DKK1 was proven, we injected MOPC315.BM.Luc 
cells into the tail vein of 20 BALB/c mice (day -5), and five 
days later (day 0) mice were injected subcutaneously with ei-
ther the oligopeptide or vehicle alone (Fig. 4A). Tumor burden 
was measured via BLI (Fig. 4B). On day 0, no significant radi-
ance (p/sec/cm2/sr) was detected in any of the representative 
mice of three groups. In contrast, on day 28, all mice injected 
with MM cells invoked a BLI signal. Importantly, larger radi-
ances were detected in the vehicle group than in the oligo-
peptide group. No significant radiances were detected in the 
control group, as no cells were injected. The signals of oligo-
peptide-treated mice were predominantly detected in the 
spleen, while the signals of the vehicle-treated mice were 
more diffused all over the body, especially stronger in femur 
areas. The median radiance fold change of the vehicle group 
had the highest value, and the oligopeptide group was about 
three times lower (p=0.046) than the vehicle group (Fig. 4C). 
This data was divided into three ranges, 10 to less than 50, 50 
to 500, and more than 500. In the lower range of fold change, 
there were more mice from the oligopeptide group (n=7) than 
the vehicle group (n=3). However, in the fold changes of 50 
and higher, the number of the vehicle group mice was much 
larger (n=7) than the oligopeptide group mice (n=3) (Fig. 4D). 
All mice from the control group had fold changes of less than 
two. In accordance with the BLI results, the ELISA assessed 
M315 protein level of the peptide group showed lowering 
trend, compared to the vehicle group, with no significance 
(data not shown). This may be resulted because of the small 
number of mice in each group and their large variations of the 
M315 protein level. This observation showed that oligopep-
tide affects the growth of MM cells in vivo, although the de-
tailed mechanism remains unknown.
 
Cyclized oligopeptide has no direct effect on 
MOPC315.BM.Luc cell proliferation in vitro
One concern of using this oligopeptide is that it may affect the 
Wnt signaling pathway and stimulate cancer cell growth. In 
our in vivo experiment, however, we found that the tumor 
burdens were reduced with the treatment of the oligopeptide. 
To better define the effect of the oligopeptide on MM cell 
growth, we tested the oligopeptide in vitro, examining cell 
proliferation via WST assay. The MM cell population did not 
vary significantly in the differently treated groups (data not 
shown). This result demonstrated that oligopeptide does not 
affect MM cell growth directly, despite the MM cells exhibit-
ing a Wnt/β-catenin signaling pathway.
These overall findings indicate that the oligopeptide affects 
MM cells and osteoblastic cells; it remains uncertain as to 
how and through what kind of mechanism this oligopeptide 
affects osteoblasts and MM cells. The anti-MM effect may be 
mediated by the indirect effects on the bone microenviron-
ment by the cyclized oligopeptide. Variable factors in the mi-
croenvironment may contribute strongly to the MM tumor 
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Fig. 2. Luciferase reporter activity of cells treated with cyclized oligopeptide and ProteOn XPR36 analysis. MC3T3-E1-S-Top cells were treated with Wn-
t3a, DKK1, sclerostin, and oligopeptide. (A) This graph shows the oligopeptide bound directly to the LRP5 E1 domain and the activity response increased 
dose dependently. (B) Graph on the left shows the dose increasing with luciferase reporter activity as the concentration of the oligopeptide increased. 
However, in the graph on the right, when treated with sclerostin, the same trend is not seen. (C) The same cells were treated with Wnt7a, DKK1, scleros-
tin and oligopeptide. DKK1, dickkopf 1; LRP, lipoprotein receptor-related protein; SOST, sclerositn.
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burden; however, further studies are needed.
DISCUSSION
In the present study, we showed that a cyclized oligopeptide 
treatment reduced tumor burden in the MOPC315.BM.Luc 
MM mouse model. To study the effects of this oligopeptide 
targeting the DKK1-LRP5/6 binding pocket in MM bone dis-
ease, DKK1 NXI motif-containing cyclized oligopeptide was 
developed, and a series of in vitro and in vivo experiments 
was performed.
Wnt signaling is well known for the osteoblast lineage speci-
fication from mesenchymal cells, further differentiation of os-
teoblast precursor cells, and skeletal development.24 DKK1, 
an endogenous Wnt inhibitor, binds to LRP5/6 with Kremen 
to inhibit the canonical Wnt signaling pathway. Most MM 
cells express DKK1;14 furthermore, the secreted DKK1 disrupts 
the RANKL/OPG expression ratio, which enhances osteoclast-
mediated osteolysis and simultaneous osteoblast inhibition.15 
As DKK1 has been a potential therapeutic target for the treat-
ment of MM, some effective therapies targeting DKK1 have 
Fig. 3. Reverse transcription-PCR and Alkaline phosphatase staining assay. (A) ST2 cells were treated with Wnt7a, DKK1, and oligopeptide then the 
mRNA expression of both ALP and OPG assessed. (B) When Wnt7a alone was used, the staining was stronger than when Wnt7a and DKK1 were used 
together. The staining intensity also increased dose dependently with increasing concentration of oligopeptide treatment. Original magnification ×40. (C) 
The expressions of DKK1 and β-catenin were checked in the MOPC.315.BM.Luc cells prior to the experiment. DKK1, dickkopf 1; ALP, alkaline phosphatase; 
OPG, osteoprotegerin.
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Fig. 4. Tumor growth was reduced in the MOPC315.BM.Luc cell induced multiple myeloma mouse model. (A) A brief timeline of the animal study is shown. 
(B) One representative mouse from each group was chosen based on the closest radiance activity to the median value. Images taken on day 0 and day 
28 are shown and compared. On day 0, BLI was taken before the oligopeptide treatment. No radiance was detected in the untreated mouse. (C) Biolumi-
nescence radiance fold changes of each group from day 0 to day 28 are shown. Each group was comprised of 10 mice. (D) Mice numbers according to 
the fold changes of bioluminescence radiance are shown. Fold changes were calculated simply by dividing the final value by the initial value. *p<0.05 and 
***p<0.0001 by Mann-Whitney U test. MM, multiple myeloma.
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been developed, including DKK1 neutralizing antibodies, 
proteasome inhibitors, DKK1 vaccines, and tumor-produced 
endothelin-1.26 A study using the SCID-rab mouse model of 
myeloma showed that anti-DKK1 antibody treatment in-
creased bone formation and reduced tumor burden in a rab-
bit bone implanted with MM.19 Human anti-DKK1 monoclo-
nal antibody (BHQ880) was also found to increase osteoblasts 
and blocked MM cell proliferation when MM cells were co-
cultured with bone marrow stromal cells (BMSC).20
The cyclized oligopeptide against the DKK1-LRP5/6 bind-
ing pocket abrogated the Wnt-β-catenin signaling inhibited by 
DKK1 (not by sclerostin) dose dependently (IC50≈5×10-8 M). 
The NMR structure was obtained by complete proton reso-
nance assignment. Isoleucine residue of the cyclized peptide 
should target the second pocket of LRP5/6. A ribbon diagram 
(Fig. 1C) showed that DKK1 is a linear peptide chain with a 
loop conformation.
The MM mice model we studied was developed in the Bo-
gen lab.21 It was stated that the MM mice developed tumor 
burdens mostly around long bone areas and also developed 
tumor cells in the bone marrow. How the MM cells affect the 
bone metabolism or bone marrow, however, was not deeply 
studied. The administration of the oligopeptide abrogated the 
suppression of canonical Wnt signaling by DKK1 and inhibit-
ed tumor burden significantly. As matrix protein contains 
many growth factors and cytokines stimulating proliferation 
of tumor cells, inhibition of bone resorption by decreasing the 
RANKL/OPG ratio via the oligopeptide could reduce the re-
lease of these growth factors and cytokines from matrix pro-
teins and inhibit the overgrowth of MOPC315.BM.Luc cells. 
Similar to what we have achieved, the DKK1 neutralizing anti-
body BHQ880 has been shown to not only improve bone for-
mation but also to reduce tumor burden.20 Additionally, stud-
ies have reported that DKK1 suppressed β-catenin in myeloid-
derived suppressor cells (a heterogeneous population of 
myeloid lineage immune cells in the stromal compartment) 
and thus inhibited tumor growth in mice.27 To explore the 
mechanism of the tumor burden reduction, we studied the ef-
fects of oligopeptide on proliferation of tumor cells. However, 
we could not find any direct effects of oligopeptide on the 
proliferation of tumor cells, despite the fact that DKK1 is ex-
pressed in MOPC315.BM.Luc cells (data not shown). This re-
sult was supported by a previous study showing that, while 
BHQ-880 did not have a direct anti-tumor effect on myeloma 
cells, it inhibited myeloma growth in the presence of BMSC.20 
The MM niches contain bone marrow, fat cells, and immune 
cells, and they interact with each other. Several other cell types 
within the bone microenvironment produce significant amounts 
of DKK1, including megakaryocytes, endothelial cells, and os-
teoblasts, and may contribute to the regulation of tumor gr-
owth.28,29 TGF-β, VEGF, and FGF, as well as the increase of bone 
resorption by osteoclasts, seem to support MM cell growth.30,31 
In a previous study, DKK1 indirectly contributed to myeloma 
growth by regulating IL-6 in the bone microenvironment. 
BHQ-880 significantly reduced the production of IL-6 levels in 
BMSC supernatants, and the addition of IL-6 reversed the ma-
jority of growth inhibitory effects.20 Therefore, the overall results 
we obtained may have derived from DKK1 acting on these cells 
differently.
In conclusion, the cyclized oligopeptide based on the DKK1-
LRP5/6 interaction abrogates the suppression of canonical 
Wnt signaling by DKK1. Treatment of the oligopeptide re-
duced tumor burden significantly in the MOPC315.BM.Luc 
MM mouse model. Cyclized oligopeptide may be an option 
for proper management of tumor burden in MM; however, 
further research is required to determine the details of the 
mechanisms involved.
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